Tokyo Tape
Sign in
← ReproCELL

Quarterly report · Q2

4978.TEDINET S100S7WW
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥1.1bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥3.0bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥1.6bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥242m2023-04-01 → 2023-09-30Cons.Operating income
Operating income−¥90m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥70m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥120m2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥70m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥62m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥70m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥61m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥305m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥69m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥61m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥69m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥8.4bnat 2023-09-30Cons.Assets
Total assets¥8.4bnat 2023-03-31Cons.Assets
Total assets¥8.8bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥664mat 2023-09-30Cons.Liabilities
Total liabilities¥781mat 2023-03-31Cons.Liabilities
Net assets / equity¥7.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥7.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥7.9bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥1.9bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥2.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.9bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥58m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥141m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥61m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥46m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥541m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥483m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥485m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥0.712023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-0.132023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.622022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.822022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.312022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio92.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio90.7%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment ordinary income2023-04-01 → 2023-09-30−¥214m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥122m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥122m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentsegment ordinary income2023-04-01 → 2023-09-30¥110m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentsegment ordinary income2023-04-01 → 2023-09-30¥174m
—segment totalrevenue2023-04-01 → 2023-09-30¥1.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥1.1bn
—segment totalsegment ordinary income2023-04-01 → 2023-09-30¥284m
Reconciling Itemsreconcilingsegment ordinary income2022-04-01 → 2022-09-30−¥286m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥674m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥674m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentsegment ordinary income2022-04-01 → 2022-09-30¥222m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥903m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥903m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentsegment ordinary income2022-04-01 → 2022-09-30¥134m
—segment totalrevenue2022-04-01 → 2022-09-30¥1.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥1.6bn
—segment totalsegment ordinary income2022-04-01 → 2022-09-30¥356m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 486
ItemContextValueUnit
Net salesPrior1YTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember674028000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember1576757000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration1576757000JPY
Ordinary incomePrior1YTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember134355000JPY
Ordinary incomePrior1YTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember221863000JPY
Ordinary incomePrior1YTDDuration_ReportableSegmentsMember356218000JPY
Ordinary incomePrior1YTDDuration_ReconcilingItemsMember-286100000JPY
Ordinary incomePrior1YTDDuration70118000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember1025305000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember121834000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember1147139000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration1147139000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember1025305000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember121834000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember1147139000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration1147139000JPY
Ordinary incomeCurrentYTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember174249000JPY
Ordinary incomeCurrentYTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember110131000JPY
Ordinary incomeCurrentYTDDuration_ReportableSegmentsMember284381000JPY
Ordinary incomeCurrentYTDDuration_ReconcilingItemsMember-214105000JPY
Ordinary incomeCurrentYTDDuration70276000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-11-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第22期第２四半期（自　2023年７月１日　至　2023年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社リプロセル
Company name in english cover pageFilingDateInstantReproCELL Incorporated
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　横山　周史
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神奈川県横浜市港北区新横浜三丁目８番11号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)045-475-3887（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)CFO 兼 経営管理部GM　宗村　敏
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)神奈川県横浜市港北区新横浜三丁目８番11号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)045-475-3887（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)CFO 兼 経営管理部GM　宗村　敏
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE27585
Fund codeFilingDateInstant－
Security codeFilingDateInstant49780
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社リプロセル
Filer name in englishFilingDateInstantReproCELL Incorporated
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass